Johnson & Johnson (JNJ) sued divisions of Cigna (CI), accusing them of working with a drug-benefit middleman to drain J&J financial-assistance funds earmarked for patients taking some of its pricier drugs, widening litigation against the company against SaveOnSP, The Wall Street Journal’s Peter Loftus reported on Friday. J&J added pharmacy benefits manager Express Scripts and specialty pharmacy Accredo as defendants in an amended lawsuit that J&J filed under seal in federal court in New Jersey earlier this year, according to the report. J&J claims the Cigna units worked on a program with SaveOn that caused J&J to pay more than $100M in drug copay assistance in addition to what it would have otherwise.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- eBay downgraded, GM upgraded: Wall Street’s top analyst calls
- Johnson & Johnson reinstated with a Neutral at BofA
- J&J’s CARVYKTI shows higher rates of minimal residual disease negativity
- Gilead price target raised to $115 from $105 at Oppenheimer
- J&J announces new frontline data featuring TECVAYLI fro 2 studies in NDMM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
